- Home
- CGAU vs MESO Comparison
CGAU vs MESO Comparison
Compare CGAU & MESO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CGAU
- MESO
- Stock Information
- Founded
- CGAU 2002
- MESO 2004
- Country
- CGAU Canada
- MESO Australia
- Employees
- CGAU N/A
- MESO N/A
- Industry
- CGAU Precious Metals
- MESO Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CGAU Basic Materials
- MESO Health Care
- Exchange
- CGAU Nasdaq
- MESO Nasdaq
- Market Cap
- CGAU 1.6B
- MESO 1.3B
- IPO Year
- CGAU N/A
- MESO N/A
- Fundamental
- Price
- CGAU $7.84
- MESO $15.95
- Analyst Decision
- CGAU Buy
- MESO Buy
- Analyst Count
- CGAU 2
- MESO 4
- Target Price
- CGAU $13.00
- MESO $18.00
- AVG Volume (30 Days)
- CGAU 1.5M
- MESO 132.1K
- Earning Date
- CGAU 08-06-2025
- MESO 08-28-2025
- Dividend Yield
- CGAU 2.55%
- MESO N/A
- EPS Growth
- CGAU N/A
- MESO N/A
- EPS
- CGAU 0.33
- MESO N/A
- Revenue
- CGAU $1,214,156,000.00
- MESO $5,670,000.00
- Revenue This Year
- CGAU $6.05
- MESO $196.73
- Revenue Next Year
- CGAU $9.39
- MESO $286.51
- P/E Ratio
- CGAU $23.97
- MESO N/A
- Revenue Growth
- CGAU N/A
- MESO N/A
- 52 Week Low
- CGAU $5.41
- MESO $6.00
- 52 Week High
- CGAU $7.90
- MESO $22.00
- Technical
- Relative Strength Index (RSI)
- CGAU 61.36
- MESO 58.99
- Support Level
- CGAU $7.68
- MESO $14.68
- Resistance Level
- CGAU $7.87
- MESO $16.27
- Average True Range (ATR)
- CGAU 0.22
- MESO 0.42
- MACD
- CGAU 0.07
- MESO -0.06
- Stochastic Oscillator
- CGAU 93.20
- MESO 75.14
About CGAU Centerra Gold Inc.
Centerra Gold Inc a gold mining and exploration company engaged in the operation, exploration, development, and acquisition of gold properties in Asia, North America, and other markets world-wide. The company reportable operating segments are Oksut; Mount; and Milligan Molybdenum. It derives maximum revenue from Oksut segment. Geographically, it operates in Turkey, United States, Canada and Other.
About MESO Mesoblast Limited
Mesoblast Ltd is a biotechnology company. It uses its proprietary technology platform to develop and commercialize allogeneic cellular medicines to treat complex diseases resistant to conventional standards of care and where inflammation plays a central role. The company's product candidates include; Ryoncil (remestemcel-L) for the treatment of steroid refractory acute graft versus host disease as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of cell technology platform for commercialization.